Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. - Wikidata - wikimedia - TriplyDB

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

http://www.wikidata.org/entity/Q36535062

about

Neoplastic disease after liver transplantation: Focus on de novo neoplasms Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Therapeutic targeting of replicative immortality Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Role of insulin receptor substrates in the progression of hepatocellular carcinoma.Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo.MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.DNA markers in molecular diagnostics for hepatocellular carcinoma.Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma.Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.The Antiproliferative Effect of Cyclodipeptides from Pseudomonas aeruginosa PAO1 on HeLa Cells Involves Inhibition of Phosphorylation of Akt and S6k Kinases.Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.MicroRNA-144-3p inhibits proliferation and induces apoptosis of human salivary adenoid carcinoma cells via targeting of mTOR.The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats.Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR.Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling.Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.Report of the Signal Transduction Society Meeting 2017-Metabolism in Health and Disease.Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma.Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling

P2860

Q26798306-CE1DD696-EC3E-4FC4-B574-CE00AE25E0CB Q26798462-3AA7B01B-378B-4F97-A39D-B7B5304C6024 Q26830194-EC63AB73-83D6-45A8-ABEF-649B3D198A7C Q27027457-D24F6503-0C62-4490-A38D-113C73967A72 Q30313117-40B926D1-CED1-4EFA-A548-8EC066812D94 Q33905578-B873FCF1-0A1A-4369-8285-BE56CB2149D5 Q34075366-0F5CE6FE-33E1-4926-858F-0681601F2446 Q35123077-F91DFE60-8F71-4BE8-AF1A-A869D2A279EE Q35775057-BB35F675-44C3-47F2-8499-54C16565D8A2 Q35781255-7E75C189-480B-4564-8832-E91B007E8982 Q36414381-2B071B3B-22B2-4EFE-BC89-524DF8D5B56F Q37299276-25F7AC33-AB41-4162-8CFD-8E0FAF111F90 Q37438760-9E148E53-5975-405E-9C4E-E40F75466DC0 Q37536415-D899C0D2-4DB1-4B20-BB84-19024D89BD9F Q37563910-B91CE57A-3852-4A61-975B-0C97839B392F Q37619833-0364D5FA-8E7E-4825-A817-E578E16C2ABB Q37641827-ADF0C32B-A924-410E-BB57-872FAA1B4E51 Q37707078-CBA095B8-C3B2-47BD-A64D-20FC3B005AD9 Q38195885-146D01FC-C887-4F2F-BB7A-CF78B2F756EE Q38699679-84312B60-967C-4A89-8E9D-137418ABC02F Q38714871-5D96C809-0CF3-4B6D-B0D9-3ACA42A69B98 Q38810281-00258830-67A2-49C3-84AF-EE9DE46B6F47 Q38871688-5AD66834-89BB-44D0-8027-91E29DCE41A7 Q38878979-8680C2E9-AC7F-4A9E-97A9-B8B0E4323F5E Q38931801-7974FF3F-E7C2-4873-8A1D-4533994726F5 Q38946509-A428BF01-E970-4CCD-99E7-B7D391CFA402 Q38969795-9ADDA343-9E2A-420F-A63A-011999CD64AB Q39035073-E2C02B5F-13C1-493A-AA2A-52A4E6165A08 Q39044797-3854B724-C0BF-455A-975B-37863DC93873 Q39119297-2116A51D-48DA-4001-AD02-8740DB2CCCC7 Q39140529-3C685B60-3963-4EED-BA5B-86B5EBB8EC10 Q39147611-0B033BD7-EC0E-49CD-9C68-6F147C55C4D9 Q41854656-778F8525-FFA5-4876-BC7C-7C0D28DD3663 Q47094892-B1618BC4-FB3D-40D8-88A3-8B2E3472C3C5 Q48853960-79BC0AB9-2C29-4976-88F5-7CAF310D9232 Q50033865-ED9C07F4-1EC0-4037-A05D-889B3C04CDF4 Q52784526-F93B751D-FEFB-42ED-A8A8-1C0507DF0578 Q55003892-1592CB88-0702-4E81-B7EA-709B0D1FC84B Q57287873-D233704F-2A44-465D-98F8-132C75557473

P2860

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

http://www.wikidata.org/entity/Q36535062

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@ast

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@en

type

label

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@ast

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@en

prefLabel

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@ast

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@en

P1433

Q36535062-9713D17B-6E6E-404A-A7E3-097DED2631B3

P1476

Q36535062-BA5960FF-D84F-4000-9CA8-ADE639676C90

P2093

Q36535062-1F91CE9E-521D-441B-A2C0-5AF78E73A865

Q36535062-366138C6-DBC1-4E51-BBD4-D38ED70759E4

Q36535062-51AEA3EE-FCE9-46AB-9784-52469F3ED4FC

Q36535062-87A4B387-0EBD-42EA-8881-96E9AD6795F7

Q36535062-9CAE155A-16E0-434C-96CC-2DF8243F5927

Q36535062-DCB39622-3891-4AFF-A951-58BEDD074DF0

Q36535062-E60C458A-EC4A-4A72-BA2E-DA4132DB0C74

P2860

Q36535062-0161874E-05AB-4D23-A87A-B64D43231DE9

Q36535062-085CACC6-41C9-49A8-A955-95196764F2FD

Q36535062-0E1FF9D6-223E-4EFC-B9E3-A0EBB4B48D65

Q36535062-26EF2C08-CBA4-4E78-915D-AA442DA98672

Q36535062-3DE91303-9B63-40FB-9E4E-9D6CAF838982

Q36535062-425F707D-3F92-4711-AA96-240E60EA5938

Q36535062-4DC6F80B-B05A-468B-8621-7772AEB6529F

Q36535062-4EA597D3-B6A1-4149-B4BE-26A96FA89BE6

Q36535062-562A6594-FA75-4580-886F-79FE0F9E84E8

Q36535062-5D53A7F1-A49E-40B4-8DA2-93E2E40C8448

P2888

Q36535062-15762D1E-26F1-443B-8826-51201A7BED63

P304

Q36535062-079460C4-C1BE-4E98-ABE1-CA5E908D680E

P31

Q36535062-A70E31B6-2BA4-4632-B254-CC7E99EF77E4

P356

Q36535062-A2FA0FFF-2DFF-49AD-AB09-030902D16B48

P478

Q36535062-A062F251-086E-4B4F-9D36-FED416D3D697

P577

Q36535062-3E9E3C89-8066-49AF-A419-F0E8CD35FC37

P5875

Q36535062-CF50C0AD-7F6C-4955-B2ED-BFD1AFB2F74E

P6179

Q36535062-E16539A2-7FCA-43C6-A686-82FBF5411C05

P698

Q36535062-6A94260B-ADB7-4E9B-825A-9294105E8099

P932

Q36535062-5E304F4D-BE62-4091-A416-50AC78E67603

P356

1476-4598-11-85

P1433

Molecular Cancer

P1476

Combined targeting of AKT and ...... epatocellular carcinoma cells.

@en

P2093

Bianca T Hofmann

http://www.w3.org/2001/XMLSchema#string

Björn Nashan

http://www.w3.org/2001/XMLSchema#string

Florian Ewald

http://www.w3.org/2001/XMLSchema#string

Katharina Staufer

http://www.w3.org/2001/XMLSchema#string

Manfred Jücker

http://www.w3.org/2001/XMLSchema#string

Nicole Grabinski

http://www.w3.org/2001/XMLSchema#string

Udo Schumacher

http://www.w3.org/2001/XMLSchema#string

P2860

A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Targeting the mTOR signaling network for cancer therapy

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Sorafenib in advanced hepatocellular carcinoma

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling.

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

P2888

1476-4598-11-85

P304

85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-11-85

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233736831

http://www.w3.org/2001/XMLSchema#string

P6179

1032052903

http://www.w3.org/2001/XMLSchema#string

P698

23167739

http://www.w3.org/2001/XMLSchema#string

P932

3545733

http://www.w3.org/2001/XMLSchema#string